Literature DB >> 33970462

Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy.

Indra Rautela1, Aditi Sharma2, Pallavi Dheer3, Priya Thapliyal4, Shweta Sahni5, Vimlendu Bhushan Sinha6, Manish Dev Sharma7.   

Abstract

Along with the evolutionary breakthrough of RNA interference and the applicability for gene knockdown, a subsequent development in siRNA-based therapeutics has been attained. The gene therapy based on RNAi is in transition progress from the research aspects to clinical base. Being a potent tool, siRNA is used as therapeutic against several disorders. Cancer which is one of the deadliest diseases is now treated with an advanced mechanism of siRNA delivery inside the genome, leading to gene silencing; thereby, blocking translation of gene to form protein. siRNA tool delivers remedial effects with the advantages of safe delivery and efficiency. Despite its merits, barriers including instability at physiological conditions, lack of ability to cross biological membranes, off-targets, and safety are also associated with siRNA delivery system. The gene silencing efficiency values both in vitro and in vivo reported in the past years have been reviewed by material type (lipid, polymer, silica, porous silicon, and metal). This review presents a deep insight in the development of targeted delivery of siRNA. Since several clinical trials have also been performed regarding the siRNA delivery against cancer, it can also be stated that the delivery system should be good enough to achieve effective siRNA drug development.
© 2021. Controlled Release Society.

Entities:  

Keywords:  Cancer therapy; Gene knockdown; Gene silencing; RNA interference; siRNA

Mesh:

Substances:

Year:  2021        PMID: 33970462     DOI: 10.1007/s13346-021-00995-6

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  60 in total

1.  Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

Authors:  Veit Hornung; Margit Guenthner-Biller; Carole Bourquin; Andrea Ablasser; Martin Schlee; Satoshi Uematsu; Anne Noronha; Muthiah Manoharan; Shizuo Akira; Antonin de Fougerolles; Stefan Endres; Gunther Hartmann
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

2.  Evaluating the Mechanisms of Light-Triggered siRNA Release from Nanoshells for Temporal Control Over Gene Regulation.

Authors:  Rachel S Riley; Megan N Dang; Margaret M Billingsley; Baxter Abraham; Lars Gundlach; Emily S Day
Journal:  Nano Lett       Date:  2018-05-02       Impact factor: 11.189

Review 3.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.

Authors:  Aimee L Jackson; Peter S Linsley
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 4.  Current status and future perspectives of gold nanoparticle vectors for siRNA delivery.

Authors:  Álvaro Artiga; Inés Serrano-Sevilla; Laura De Matteis; Scott G Mitchell; Jesús M de la Fuente
Journal:  J Mater Chem B       Date:  2019-01-18       Impact factor: 6.331

Review 5.  Activation of the mammalian immune system by siRNAs.

Authors:  Joao T Marques; Bryan R G Williams
Journal:  Nat Biotechnol       Date:  2005-11       Impact factor: 54.908

6.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

7.  Principles of cancer therapy: oncogene and non-oncogene addiction.

Authors:  Ji Luo; Nicole L Solimini; Stephen J Elledge
Journal:  Cell       Date:  2009-03-06       Impact factor: 41.582

Review 8.  From human genome to cancer genome: the first decade.

Authors:  David A Wheeler; Linghua Wang
Journal:  Genome Res       Date:  2013-07       Impact factor: 9.043

9.  Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma.

Authors:  Wing Yin Tong; Mohammed Alnakhli; Richa Bhardwaj; Sinoula Apostolou; Sougata Sinha; Cara Fraser; Tim Kuchel; Bryone Kuss; Nicolas H Voelcker
Journal:  J Nanobiotechnology       Date:  2018-04-13       Impact factor: 10.435

Review 10.  Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.

Authors:  Ghanbar Mahmoodi Chalbatani; Hassan Dana; Elahe Gharagouzloo; Santiago Grijalvo; Ramon Eritja; Craig D Logsdon; Fereidoon Memari; Seyed Rouhollah Miri; Mahdi Rezvani Rad; Vahid Marmari
Journal:  Int J Nanomedicine       Date:  2019-05-02
View more
  1 in total

Review 1.  Targeting Splicing Factor SRSF6 for Cancer Therapy.

Authors:  Wenting She; Jun Shao; Rong Jia
Journal:  Front Cell Dev Biol       Date:  2021-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.